Evidence map›Paper›PMID 38418892›Full record

ArticleProstate cancer and prostatic diseases2025

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.

Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia and 14 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026
    Review
  5. B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Computational analysis of treatment resistant cancer cells.Frontiers in cell and developmental biology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 1 country.

Nicholas A Zorko *Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA. zorko004@umn.edu.ORCID http://orcid.org/0000-0001-7021-968X
Allison Makovec *Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.ORCID http://orcid.org/0009-0008-2487-9079
Andrew ElliottCaris Life Sciences, Phoenix, AZ, USA.
Samuel KellenMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
John R LozadaMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Ali T ArafaMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Martin FelicesMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Madison ShackelfordMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Pedro BarataUniversity Hospital Seidman Cancer Center, Cleveland, OH, USA.
Yousef ZakhariaHolden Comprehensive Cancer Center, Iowa City, IA, USA.ORCID http://orcid.org/0000-0001-9480-2626
Vivek NarayanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8205-738X
Mark N SteinHerbert Irving Comprehensive Cancer Center, Columbia University New York, New York, NY, USA.
Kevin K ZarrabiSidney Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA, USA.
Akash PatnaikUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Milan RadovichCaris Life Sciences, Phoenix, AZ, USA.
George SledgeCaris Life Sciences, Phoenix, AZ, USA.
Wafik S El-DeiryLegorreta Cancer Center, Brown University, Providence, RI, USA.
Elisabeth I HeathKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0003-1381-2713
Dave S B HoonSaint John's Cancer Institute, Saint John's Health Center PHS, Santa Monica, CA, USA.
Chadi NabhanCaris Life Sciences, Phoenix, AZ, USA.
Jeffrey S MillerMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Justin H HwangMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Emmanuel S AntonarakisMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-0031-9655
University of Minnesota · USCaris Life Sciences (United States) · USBrown University · USColumbia University Irving Medical Center · USEmory University · USSaint John's Health Center · USSidney Kimmel Cancer Center · USUniversity Hospitals Seidman Cancer Center · USUniversity of Chicago · USUniversity of Iowa · USUniversity of Pennsylvania · USWayne State University · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate CancerR01CA273914 · NCI · UNIVERSITY OF CHICAGO · PI PATNAIK, AKASH · 2022 to 2025
$2.6M
Inducing NK cells to remember and fight cancerR01HL122216 · NHLBI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2018
$1.5M
American Society of Hematology (ASH) Medical Student Minority AwardNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA273914NCI NIH HHS R35 CA197292NCI NIH HHS R35 CA283892NHLBI NIH HHS R01 HL122216NIGMS NIH HHS T32 GM008244Prostate Cancer Foundation (PCF) 22YOUN08U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0341U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0535U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0659U.S. Department of Defense (United States Department of Defense) W81XWH-21-1-0255U.S. Department of Defense (United States Department of Defense) W81XWH2110255U.S. Department of Defense (United States Department of Defense) W81XWH-22-1-0242
6 · The paper itself

Abstract

backgroundNatural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline.

methodsDNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N = 90,916 for all cancers and N = 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan-Meier estimates were calculated. Statistical significance was determined using X

resultsIn both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2-9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response.

conclusionsUsing the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.

Indexed as

Killer Cells, NaturalLymphocytes, Tumor-InfiltratingProstatic NeoplasmsBiomarkers, TumorHumansMalePrognosisTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID38418892
PMCPMC11349934
OpenAlexW4392239353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.